Loading clinical trials...
Loading clinical trials...
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Booster Dose of a Recombinant Multiclade HIV-1 Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP, in Uninfected Subjects Who Were Previously Immunized With VRC-HIVDNA009-00-VP in VRC 004
Conditions
Interventions
VRC-HIVADV014-00-VP booster
VRC-HIVADV014-00-VP
Locations
1
United States
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
Start Date
January 18, 2005
Completion Date
October 10, 2007
Last Updated
July 2, 2017
NCT00090662
NCT07310264
NCT06290258
NCT06716502
NCT07483606
NCT07310901
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions